Rhea-AI Summary
Bonus BioGroup (TASE: BONS), an Israeli biotechnology company, announced its drug MesenCure can effectively reduce inflammatory overreactions in cancer patients undergoing immunotherapy. A preclinical trial conducted at The Jackson Laboratory revealed that MesenCure significantly mitigates life-threatening conditions such as cytokine release syndrome, impacting up to 78% of such patients. By 2027, over 18,000 patients in the US are projected to suffer from this complication. The company is also advancing MesenCure for severe COVID treatment towards a Phase III trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
FAQ
What is the current stock price of Bonus BioGroup (BBIXF)?
Bonus BioGroup (BBIXF) last closed at $0.0400.
What is the market cap of Bonus BioGroup (BBIXF)?
The market cap of Bonus BioGroup (BBIXF) is approximately $46.7M.